Utilization And Implementation Of Inpatient Transmission Of Pa Pressures Using Cardiomems Sensor During Heart Failure Admission- A Single Center Experience.
HFSA ePoster Library. Bionat S. 09/10/21; 343657; 97
Dr. Susan Bionat
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Introduction: Heart failure patients with recovered left ventricular ejection fraction (HFrecEF) i.e. LVEF >40% have distinct pathophysiology compared to those with preserved ejection (HFpEF); however differences in clinical characteristics and outcomes of these patients remain unclear.
Hypothesis: We hypothesized that patients with HFpEF when compared with HFrecEF have higher prevalence of comorbidities and greater risk of overall mortality.
Methods: We queried our health system and identified patients with LVEF <40% who then recovered and sustained their LVEF to>40% from 2009-2018 (n=705) and propensity-matched based upon age and gender to HFpEF patients (LVEF >50%; n=3525) in 1:5 ratio. Kaplan Meier curves and multivariate Cox models compared the risk of death between two groups.
Results: At the time of first encounter, HFpEF patients were more likely to have diabetes, hypertension, chronic kidney disease, pulmonary hypertension, and cancers (p value for all<0.05). On follow up (mean 3.3 years), 1053 patients died. Kaplan Meier curves showed HFpEF patients to have increased risk of death when compared to HFrecEF patients (Figure). Multivariable Cox models also showed higher risk of death in HFpEF patients compared to HFrecEF patients (Hazard Ratio 1.71, 95% CI 1.41 -2.08; p<0.0001).
Conclusions: HFpEF patients have significantly higher prevalence of comorbidities and greater risk of death compared to the HFrecEF patients. Further research to examine causal pathways of developing HFpEF and reducing mortality are warranted.
Hypothesis: We hypothesized that patients with HFpEF when compared with HFrecEF have higher prevalence of comorbidities and greater risk of overall mortality.
Methods: We queried our health system and identified patients with LVEF <40% who then recovered and sustained their LVEF to>40% from 2009-2018 (n=705) and propensity-matched based upon age and gender to HFpEF patients (LVEF >50%; n=3525) in 1:5 ratio. Kaplan Meier curves and multivariate Cox models compared the risk of death between two groups.
Results: At the time of first encounter, HFpEF patients were more likely to have diabetes, hypertension, chronic kidney disease, pulmonary hypertension, and cancers (p value for all<0.05). On follow up (mean 3.3 years), 1053 patients died. Kaplan Meier curves showed HFpEF patients to have increased risk of death when compared to HFrecEF patients (Figure). Multivariable Cox models also showed higher risk of death in HFpEF patients compared to HFrecEF patients (Hazard Ratio 1.71, 95% CI 1.41 -2.08; p<0.0001).
Conclusions: HFpEF patients have significantly higher prevalence of comorbidities and greater risk of death compared to the HFrecEF patients. Further research to examine causal pathways of developing HFpEF and reducing mortality are warranted.
Introduction: Heart failure patients with recovered left ventricular ejection fraction (HFrecEF) i.e. LVEF >40% have distinct pathophysiology compared to those with preserved ejection (HFpEF); however differences in clinical characteristics and outcomes of these patients remain unclear.
Hypothesis: We hypothesized that patients with HFpEF when compared with HFrecEF have higher prevalence of comorbidities and greater risk of overall mortality.
Methods: We queried our health system and identified patients with LVEF <40% who then recovered and sustained their LVEF to>40% from 2009-2018 (n=705) and propensity-matched based upon age and gender to HFpEF patients (LVEF >50%; n=3525) in 1:5 ratio. Kaplan Meier curves and multivariate Cox models compared the risk of death between two groups.
Results: At the time of first encounter, HFpEF patients were more likely to have diabetes, hypertension, chronic kidney disease, pulmonary hypertension, and cancers (p value for all<0.05). On follow up (mean 3.3 years), 1053 patients died. Kaplan Meier curves showed HFpEF patients to have increased risk of death when compared to HFrecEF patients (Figure). Multivariable Cox models also showed higher risk of death in HFpEF patients compared to HFrecEF patients (Hazard Ratio 1.71, 95% CI 1.41 -2.08; p<0.0001).
Conclusions: HFpEF patients have significantly higher prevalence of comorbidities and greater risk of death compared to the HFrecEF patients. Further research to examine causal pathways of developing HFpEF and reducing mortality are warranted.
Hypothesis: We hypothesized that patients with HFpEF when compared with HFrecEF have higher prevalence of comorbidities and greater risk of overall mortality.
Methods: We queried our health system and identified patients with LVEF <40% who then recovered and sustained their LVEF to>40% from 2009-2018 (n=705) and propensity-matched based upon age and gender to HFpEF patients (LVEF >50%; n=3525) in 1:5 ratio. Kaplan Meier curves and multivariate Cox models compared the risk of death between two groups.
Results: At the time of first encounter, HFpEF patients were more likely to have diabetes, hypertension, chronic kidney disease, pulmonary hypertension, and cancers (p value for all<0.05). On follow up (mean 3.3 years), 1053 patients died. Kaplan Meier curves showed HFpEF patients to have increased risk of death when compared to HFrecEF patients (Figure). Multivariable Cox models also showed higher risk of death in HFpEF patients compared to HFrecEF patients (Hazard Ratio 1.71, 95% CI 1.41 -2.08; p<0.0001).
Conclusions: HFpEF patients have significantly higher prevalence of comorbidities and greater risk of death compared to the HFrecEF patients. Further research to examine causal pathways of developing HFpEF and reducing mortality are warranted.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}